China's Yipin Pharmaceutical raises tens of millions in yuan for anaesthetics push

What's the deal? Hebei Yipin PharmaceuticalDealroom has a profile for this one. Try Dealroom →, a Chinese anaesthetics developer, has closed an early-stage equity round worth tens of millions of yuan. Hebei Puenfengshi Venture Capital led the round, with the Shijiazhuang Metropolitan Circle Collaborative Development Equity Investment Fund among the investors joining.

What's the endgame? Yipin handles its own research, development, production, and sales. Its product lines span inhalation anaesthetics led by sevoflurane, injectable anaesthetics led by propofol, calcium-based raw materials, and specialty products such as pantoprazole sodium.

Why now? The round was announced in September 2026, giving the company fresh capital as it builds out its anaesthesia and specialty drug portfolio.

The signal: The deal reflects continued interest from regional Chinese funds in domestic pharmaceutical developers. Backing from a Shijiazhuang-linked fund points to local government-aligned capital supporting Hebei-based drugmakers.

Image credit: Generated with Gemini